LON:MXCT MaxCyte - MXCT Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. GBX 460 0.00 (0.00%) (As of 01/27/2023 07:40 PM ET) Add Compare Share Share Today's Range 452▼ 47050-Day Range 410▼ 55052-Week Range 280▼ 650Volume3,472 shsAverage Volume10,010 shsMarket Capitalization£469.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines About MaxCyte (LON:MXCT) StockMaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Stock News HeadlinesJanuary 29, 2023 | finance.yahoo.comA fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impressJanuary 4, 2023 | marketwatch.comMaxCyte, Catamaran Bio Sign Strategic Platform LicenseJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 21, 2022 | finance.yahoo.comMaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerDecember 14, 2022 | msn.comMaxCyte Earnings Perspective: Return On Capital EmployedDecember 5, 2022 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable DiseasesNovember 19, 2022 | finance.yahoo.comInsiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566mNovember 12, 2022 | seekingalpha.comMaxCyte, Inc. (MXCT) Q3 2022 Earnings Call TranscriptJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 9, 2022 | finance.yahoo.comMaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue EstimatesNovember 9, 2022 | finance.yahoo.comMaxCyte Reports Third Quarter 2022 Financial ResultsOctober 18, 2022 | finance.yahoo.comShould You Invest in MaxCyte (MXCT)?October 12, 2022 | finance.yahoo.comMaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022October 6, 2022 | finance.yahoo.comMaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood DisordersSeptember 28, 2022 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing ProgramSeptember 21, 2022 | bizjournals.comMontgomery County biotech MaxCyte unveils new HQ to expand headcount, manufacturingSeptember 21, 2022 | finance.yahoo.comMaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech CorridorSeptember 13, 2022 | finance.yahoo.comIs it a Good Time to Dispose Your MaxCyte (MXCT) Shares?August 9, 2022 | msn.comA Preview Of MaxCyte's EarningsJuly 12, 2022 | finance.yahoo.comMaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T ProgramsMay 13, 2022 | finance.yahoo.comMaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 yearsMay 9, 2022 | seekingalpha.comMaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Reports First Quarter Financial ResultsMay 9, 2022 | finance.yahoo.comMaxCyte Reports First Quarter Financial ResultsApril 20, 2022 | finance.yahoo.comMaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022April 13, 2022 | marketwatch.comMaxCyte CFO Resigns, Ron Holtz Appointed in Interim; Sees 1Q Revenue UpApril 13, 2022 | proactiveinvestors.comMaxCyte sales surge, CFO stands downSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:MXCT CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio5.91 Current Ratio15.05 Quick Ratio14.38 Sales & Book Value Annual Sales£41.99 million Price / Sales11.18 Cash FlowGBX 233.27 per share Price / Cash Flow1.97 Book ValueGBX 249.70 per share Price / Book1.84Miscellaneous Outstanding Shares102,047,000Free FloatN/AMarket Cap£469.42 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Douglas Arthur Doerfler (Age 67)Founder, Pres, CEO & Exec. Director Comp: $1.39MMr. Ronald Evan Holtz CPA (Age 65)Ph.D., Chief Financial Officer Comp: $649.38kDr. J. Stark Thompson Ph.D. (Age 81)Consultant Comp: $84.71kDr. Cenk Sumen (Age 50)Chief Scientific Officer Mr. Sean MenarguezDirector of Investor RelationsMr. Maher Masoud (Age 48)Exec. VP, Gen. Counsel & Sec. Mr. Thomas Michael Ross (Age 62)Exec. VP of Global Sales Dr. James Brady Ph.D.Sr. VP of Technical Applications & Customer SupportDr. Sarah Haecker Meeks Ph.D.Sr. VP of Bus. Devel.Mr. James LovgrenSr. VP of Global MarketingMore ExecutivesKey CompetitorsSilence TherapeuticsLON:SLNAmryt PharmaLON:AMYTConsort Medical plc (CSRT.L)LON:CSRTOxford BiomedicaLON:OXBAvacta GroupLON:AVCTView All Competitors MXCT Stock - Frequently Asked Questions How have MXCT shares performed in 2023? MaxCyte's stock was trading at GBX 437.50 on January 1st, 2023. Since then, MXCT shares have increased by 5.1% and is now trading at GBX 460. View the best growth stocks for 2023 here. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC). What is MaxCyte's stock symbol? MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT." How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is MaxCyte's stock price today? One share of MXCT stock can currently be purchased for approximately GBX 460. How much money does MaxCyte make? MaxCyte (LON:MXCT) has a market capitalization of £469.42 million and generates £41.99 million in revenue each year. How can I contact MaxCyte? MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The official website for the company is www.maxcyte.com. The company can be reached via phone at +1-301-9441700. This page (LON:MXCT) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.